Toggle Main Menu Toggle Search

Open Access padlockePrints

A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy

Lookup NU author(s): Dr Patrick Yu Wai Man, Dr Sanatan Chattopadhyay, Philip Griffiths, Professor Patrick Chinnery

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Major advances in understanding the pathogenesis of inherited metabolic disease caused by mitochondrial DNA mutations have yet to translate into treatments of proven efficacy. Leber’s hereditary optic neuropathy is the most common mitochondrial DNA disorder causing irreversible blindness in young adult life. Anecdotal reports support the use of idebenone in Leber’s hereditary optic neuropathy, but this has not been evaluated in a randomized controlled trial. We conducted a 24-week multi-centre double-blind, randomized, placebo-controlled trial in 85 patients with Leber’s hereditary optic neuropathy due to m.3460G>A, m.11778G>A, and m.14484T>C or mitochondrial DNA mutations. The active drug was idebenone 900 mg/day. The primary end-point was the best recovery in visual acuity. The main secondary end-point was the change in best visual acuity. Other secondary end-points were changes in visual acuity of the best eye at baseline and changes in visual acuity for both eyes in each patient. Colour-contrast sensitivity and retinal nerve fibre layer thickness were measured in subgroups. Idebenone was safe and well tolerated. The primary end-point did not reach statistical significance in the intention to treat population. However, post hoc interaction analysis showed a different response to idebenone in patients with discordant visual acuities at baseline; in these patients, all secondary end-points were significantly different between the idebenone and placebo groups. This first randomized controlled trial in the mitochondrial disorder, Leber’s hereditary optic neuropathy, provides evidence that patients with discordant visual acuities are the most likely to benefit from idebenone treatment, which is safe and well tolerated.


Publication metadata

Author(s): Klopstock T, Yu-Wai-Man P, Dimitriadis K, Rouleau J, Heck S, Bailie M, Atawan A, Chattopadhyay S, Schubert M, Garip A, Kernt M, Petraki D, Rummey C, Leinonen M, Metz G, Griffiths PG, Meier T, Chinnery PF

Publication type: Article

Publication status: Published

Journal: Brain

Year: 2011

Volume: 134

Issue: 9

Pages: 2677-2686

Print publication date: 25/07/2011

ISSN (print): 0006-8950

ISSN (electronic): 1460-2156

Publisher: Oxford University Press

URL: http://dx.doi.org/10.1093/brain/awr170

DOI: 10.1093/brain/awr170


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
Association Francaise contre les Myopathies
Deutsche Forschungsgemeinschaft (DFG)
Medical Research Council (UK)
UK National Institute of Health
BMBF
German Ministry of Education and Research (BMBF, Bonn, Germany)
Parkinson's UK
UK Mitochondrial Disease Cohort
UK NIHR Biomedical Research Centre for Ageing and Age-related disease
Wellcome Trust
01GM0862German network for mitochondrial disorders (mitoNET)

Share